Hospital Universitario Virgen de la Victoria
Málaga, Spain
NCT Number: NCT01733368
Optimization and evolution of the patient will be evaluated over 6 months after the implant.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Málaga, Spain
Patient will be enrolled into the study after Informed Consent signature and CRT-D+quadripolar (QuartetTM) LV lead.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months after implant
Structural remodelling is defined as a reduction >15% in Left Ventricle End Systolic Volume (LVESV), measured 6 months after implant.
Time frame: 6 months after implant
Time frame: 6 months after implant
Response is defined as a reduction >15% in LVESV, measured 6 months after implant.
Non-conventional pacing vectors are the pacing vectors exclusive to the Quartet LV quadripolar lead, not available in the conventional bipolar leads.
Time frame: 6 months after implant
Response is defined as a reduction >15% in LVESV, measured 6 months after implant.
Conventional pacing vectors are the pacing vectors available both in the Quartet LV quadripolar lead and in the conventional bipolar leads.
Abbott Medical Devices
Industry
Observational Study to Evaluate the Management of Patients Resynchronized With the QuartetTM LV Quadripolar Lead
Acronym: QUARTO-II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05750953
Cardiovascular Diseases, Colon Rectal Cancer
Stavanger, Rogaland, Norway
View Trial DetailsNCT02061319
Cardiovascular Diseases, Heart Diseases
Ottawa, Ontario, Canada
View Trial DetailsNCT06576050
Body Weight, Body Weight Changes
Boston, Massachusetts, United States
View Trial DetailsNCT04113109
Cardiovascular Diseases, Heart Diseases
Nashville, Tennessee, United States
View Trial Details